The burden of preserved ejection fraction heart failure in a real-world Swedish patient population

References

• Allender S, Scarborough P, Peto V, et al. European Cardiovascular Disease Statistics: 2008 Edition. British Heart Foundation Health Promotion Research Group, Department of Public Health and Health Economics Research Centre. University of Oxford, London, England, 2008
   Google Scholar
• Cline CMJ, Boman K, Holst M, et al.; for the Swedish Society of Cardiology Working Group for Heart Failure. The management of heart failure in Sweden. Eur J Heart Fail 2002;4:373-6
   PubMed Web of Science ®Google Scholar
• Schwinger RHG. Pathophysiology of heart failure. Clin Res Cardiol Suppl 2010;5:16-20
   Google Scholar
• Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care 2005;23:227-32
   PubMed Web of Science ®Google Scholar
• Mejhert M, Persson H, Edner M, et al. Epidemiology of heart failure in Sweden—a national survey. Eur J Heart Fail 2001;3:97-103. PubMed PMID:11163742
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9
   PubMed Web of Science ®Google Scholar
• From AM, Borlaug BA. Heart failure with preserved ejection fraction: pathophysiology and emerging therapies. Cardiovasc Ther 2010;29:e6-21
   Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
   PubMed Web of Science ®Google Scholar
• Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil 2009;16:576-82
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Stalhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010;24:263-73
   PubMed Web of Science ®Google Scholar
• Carlsson A, Borgström F, Stålhammar J, et al. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics 2004;22(3 Suppl):25-35
   PubMed Web of Science ®Google Scholar
• Ringborg A, Martinell M, Stålhammar J, et al. Resource use and costs of type 2 diabetes in Sweden – estimates from population-based register data. Int J Clin Pract 2008;62:708-16
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Stålhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Human Hypertension 2010;24:263-73
   PubMed Web of Science ®Google Scholar
• Henriksson M, Russell D, Bodegard J, et al. Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Human Hypertension 2010;25:130-6
   PubMed Web of Science ®Google Scholar
• Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2001;3:97-103
   PubMedGoogle Scholar
• Rydén-Bergsten T, Andersson F. The healthcare costs of heart failure in Sweden. J Intern Med 1999;246:275-84
   PubMed Web of Science ®Google Scholar
• Stalhammar J, Stern L, Linder R, et al. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. J Med Econ 2012;15:938-46
   PubMedGoogle Scholar
• Jonsson A, Edner M, Alehagen U, et al. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010;12:25-31
   PubMed Web of Science ®Google Scholar
• Kawashiro N, Kasanuki H, Ogawa H, et al. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J 2008;72:2015-20
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007;28:1128-34
   PubMed Web of Science ®Google Scholar
• Mehta PA, Dubrey SW, McIntyre HF, et al. Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail 2008;10:1108-16
   PubMed Web of Science ®Google Scholar
• Lund LH, Benson L, Dahlstrom U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA: the Journal of the American Medical Association 2012;308:2108-17
   PubMed Web of Science ®Google Scholar
• Campbell RT, Jhund PS, Castagno D, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? Am Coll Cardiol 2012;60:2349-56
   PubMed Web of Science ®Google Scholar